Clover Health Investments, Corp. is a remote-first healthcare technology company that operates as a large accelerated filer. As of October 30, 2026, the company had 439,707,261 shares of Class A and 95,713,497 shares of Class B common stock outstanding. The filing highlights the expansion of its Clover Assistant technology under the brand name Counterpart Assistant for external payors and providers.
Clover Health reported Q3 2026 financial results, achieving GAAP net income of $6 million and total revenue growth of 53% year-over-year to $759.3 million. The company raised its full-year 2026 guidance, now expecting total revenues between $2.97 billion and $3.00 billion and its first full year of GAAP net income profitability. Alongside the results, the company appointed Interim CFO Joseph Clay Thornton to the role on a permanent basis.
Term
Q3 2026
“Our results further demonstrate our technology-powered differentiation, and how earlier and better care management, market-leading growth, and increasing profitability can reinforce one another under the right model.”
Andrew Toy, Clover Health CEO
“In 2026, Clover is on track to have grown significantly and expects to deliver its first full year of GAAP Net Income profitability. With our largest member cohorts maturing, continued operating leverage, and strong Star ratings performance, we believe we are well positioned for meaningful earnings expansion in 2027.”